Kornimate/medical-research-clean huggingface dataset:
agmt austrian lymphoma registry

Conditions: Lymphoma

Summary: lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. they can be broadly categorized into two main types: hodgkin lymphoma (hl) and non-hodgkin lymphoma (nhl). there are different subtypes of hl, including classical hodgkin lymphoma (chl) and nodular lymphocyte-predominant hodgkin lymphoma (nlphl). the subtypes of chl include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. non-hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. common subtypes of nhl include diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), chronic lymphocytic leukemia (cll), myeloma, and other rarer subgroups. many of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities. novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis. lymphoma disease have not been systematically assessed in austria to date. this medical registry of the agmt is thus the first austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. as lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus.

this registry is designed as international multicenter observational cohort of patients with lymphoma. information on patient´s clinical presentation, tests, diagnosis, and treatment will be obtained through extraction of data from existing patient medical charts. longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. this patient follow-up data will be obtained until patient death or loss to follow-up. for documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. participation in the registry must not interfere with treatment routines. only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic case report forms (ecrf). to maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry. a written consent must be obtained prior to the input of data. no informed consent is required from deceased patients.

Eligibility criteria:
inclusion criteria: * the registry will include patients ≥ 18 years with lymphoma. exclusion criteria: * there are no specific exclusion criteria.

Keywords: lymphoma diffuse large b-cel lymphoma (dlbcl)
safety study of jtt-302 in subjects with low hdl-c levels

Conditions: Dyslipidemia

Summary: the purpose of this study is to evaluate the safety of jtt-302 when administered for eight or 12 weeks in subjects with low hdl-c levels and to determine the effect of jtt-302 on lipid parameters and cetp activity and mass.


Eligibility criteria:
inclusion criteria: * subjects must have successfully completed the 4-week treatment period of study at302-u-06-003 exclusion criteria: * females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception * use of cytochrome p450 3a4 inducers or inhibitors, as defined in the protocol * subjects who cannot follow the prescription and otc medication restrictions defined in the protocol * flu-shots not permitted during the study, including the follow-up period.
endocrine, bone and metabolic disorders in adults after allogeneic stem-cell transplant

Conditions: Endocrine System Diseases; Osteoporosis; Metabolic Syndrome; Adrenal Insufficiency

Summary: allogeneic hematopoietic stem cell transplantations (allo-hsct) is often indicated in malignant hematologic diseases. conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (tbi). endocrine complications are frequent transplant-related side effects. investigators have been well described in children studies but less in adulthood. the objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-hsct.

patients \& methods inclusion criteria are : patients treated with allo-hsct from 2006 to 2016 for a malignant hematologic disease; adult and in complete remission at exploration. exclusion criteria are : anteriority of brain radiotherapy and prior hsct. twelve months after hsct, each patient underwent fasting measurement of igf1, tsh, ft4, fsh, lh, sex steroids, glycemia, insulin level, and lipid profile. unless contraindication, adrenal and growth hormone functions were assessed with insulin hypoglycemia test. a dual x-ray absorptiometry was also performed. investigators will assess the prevalence of endocrine, bone and metabolic disorders 12 months after allo-hsct and describe some of their risk factors.

Eligibility criteria:
inclusion criteria: * patients treated with allo-hsct from 2006 to 2016 for a malignant hematologic disease * adult and in complete remission at exploration. exclusion criteria: * anteriority of brain radiotherapy * prior hsct * pregnancy
tundra gifts: harvesting local and regional resources to prevent obesity among alaska native children in remote, underserved communities

Conditions: Childhood Obesity

Summary: the long-term goal of this community based participatory research project is to prevent obesity in 3-5 year old alaska native children in remote communities. investigators will design and evaluate a culturally responsive, home-focused intervention, tundra gifts, that links early childhood education programming (i.e. head start) and federal food assistance programs (i.e. wic and snap) with primary caregivers to support healthy eating and an active lifestyle using a cluster-randomized design. the intervention integrates behavior change theory with indigenous traditional knowledge. primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a facebook site. investigators will also evaluate key process indicators of tundra gifts to understand the impact on outcomes of variations in persons and settings and to enhance the generalizability of findings.


Eligibility criteria:
inclusion criteria: * 3-5 year old children enrolled in head start and their primary caregiver in yup'ik alaska native communities

Keywords: healthy eating alaska native traditional foods
weight loss and clock 3111t/c polymorphism

Conditions: Polymorphism, Restriction Fragment Length; Obesity

Summary: the goal of this observational study is to investigate the relationship of clock 3111t/c (rs1801260) gene variant with nutritional habits, nutritional status, chronotype, sleep quality, some biochemical parameters in overweight or obese individuals and to observe its effect on weight loss diet intervention. the main questions it aims to answer are: * is the frequency of carrying the clock 3111t/c (rs1801260) gene risk allele different between individuals with normal body weight and those who are overweight or obese? * do those with the clock 3111t/c (rs1801260) risk allele have a higher frequency of evening chronotype and a shorter sleep duration? * is the effect of clock 3111t/c (rs1801260) gene alleles different on weight loss diet response in overweight or obese individuals? a questionnaire will be applied to the individuals in both groups (normal body weight and overweight/obese individuals) to evaluate their general characteristics, eating habits, adherence to mediterranean diet, dash and mind. in addition, anthropometric measurements, 3-day food consumption record and 3-day physical activity record will be taken from individuals. clock 3111t/c (rs1801260) gene variant analysis in whole blood, adiponectin and leptin hormones in serum samples will be studied. participants those who are overweight/obese will be asked to follow a weight loss diet for 3 months. researchers will compare participants with normal body weight and those who are overweight or obese to see if there is a difference between the frequency of carrying the clock 3111t/c (rs1801260) gene risk allele.


Eligibility criteria:
inclusion criteria: * be in the 20-50 age range * bmi in the range of 25-40 kg/m2 for the study group * bmi of 18.5-24.9 kg/m2 for the control group exclusion criteria: * those with type 1 diabetes * those with type 2 diabetes who take insulin therapy or use oral diabetes medication * those who use drugs for weight loss * those with unstable cardiovascular disease * those with kidney or liver failure * presence of diagnosed malabsorption (celiac disease, crohn's, ulcerative colitis) * those who have undergone bariatric surgery * those who are pregnant or breastfeeding * menopausal women * those who use corticosteroids * those with severe endocrine disorders (hypothyroidism, hyperthyroidism, hypopituitarism) * those with psychiatric or neurological disease * weight change of \>5% in the last 6 months * those with malignant tumors * those with eating disorders * shift workers * relatives * people from different ethnic backgrounds

Keywords: obesity circadian rhythm polymorphism clock gene weight loss diet
partial wave spectroscopic detection of colon cancer risk

Conditions: Ulcerative Colitis; Colon Cancer

Summary: the purpose of this study is to study samples of rectal mucosa (the moist lining of the rectum) using a new light scattering technology, called partial wave spectroscopy (pws) in patients who will undergo a standard of care colonoscopy or a flexible sigmoidoscopy and have a history of ulcerative colitis (uc).

the purpose of this study is to study samples of rectal mucosa (the moist lining of the rectum) using a new light scattering technology, called partial wave spectroscopy (pws)in patients who will undergo a colonoscopy or a flexible sigmoidoscopy and have a history of ulcerative colitis (uc). pws has been recently developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer. we believe that the pws test will more accurately detect the risk of colon cancer.

Eligibility criteria:
inclusion criteria: * patient must be 18 years old or older. * patient is already scheduled for a standard of care colonoscopy or flexible sigmoidoscopy. * patient has not received chemotherapy. * history of ulcerative colitis. exclusion criteria: * patient is unable to give informed consent.. * patient has received chemo or radiation therapy within the past 3 months.

Keywords: colonoscopy flexible sigmoidoscopy
comparing articaine and mepivacaine without palatal injection in pain assessment during maxillary teeth extraction

Conditions: Pain

Summary: this study compares the the efficacy of buccal infiltration of 4% articaine and 2% mepivacaine without any palatal injection during extraction of maxillary teeth. one group of patient receives buccal infiltration of articaine and another group receives buccal infiltration of mepivacaine.

dense local anesthesia is required to reduce pain during extraction of tooth. administration of local anesthesia to the palatal mucosa is proved to be the most painful due to its firm adherence to the underlying periosteum and also it's abundant nerve supply. articaine has greater lipid solubility and high bone penetration property. mepivacaine is proven to be the safest local anaesthetic agent. avoidance of a palatal injection during extraction will benefit the patient by reducing pain and anxiety to a greater extent. so this study compares the bone penetration property between articaine and mepivacaine by assessing the pain in the palatal mucosa while extracting the tooth using only buccal infiltration.

Eligibility criteria:
inclusion criteria: * patients aged 18 years and above * patients requiring extraction of maxillary teeth which are grossly decayed, grade i mobile, root stumps or indicated for therapeutic extractions. * healthy patients ( asa i ) or patients with mild systemic disease with no functional limitations (asa ii). * patients who are not allergic to the drugs used in the study exclusion criteria: * patients with periapical infections. * patients who are on concurrent treatment with nsaids and corticosteroids
pilot study to measure uric acid in traumatized patients: determinants and prognostic association

Conditions: Trauma; Inflammation

Summary: the goal of this project, is to better understand the fluctuation of the level of uric acid in traumatized patients by making serial measurements during their hospitalization in the intensive care unit. in addition, the determinants (e.g. type of trauma, diseases, interventions) of the blood level of uric acid and its association with the development of organ failure will be sought.


Eligibility criteria:
inclusion criteria: * direct admission to trauma center * ≤ 3h after trauma * iss ≥ 16 * received at least 1l of fluid at er entrance exclusion criteria: * isolated head injury * isolated spine injury * chemotherapy within the last month * hematologic disease * chronic hemodialysis * uricase treatment within the last week * expected death within 48h

Keywords: uric acid organ failure
evaluation of the immunogenicity and safety of varivax™ in healthy russians (v210-058)

Conditions: Varicella

Summary: the purpose of this study was to evaluate the immunogenicity and safety of varivax™ vaccine in healthy russian children, adolescents, and adults. no formal hypothesis was tested.


Eligibility criteria:
inclusion criteria: * has a negative clinical history for varicella and herpes zoster * females of reproductive potential have a negative pregnancy test prior to each study vaccination * females of reproductive potential remain abstinent or use 2 acceptable methods of birth control during study until 3 months following last study vaccination * females not of reproductive potential do not require a pregnancy test or use of contraceptives * legal representative of adult or parent of children understands risks involved with, consent to participate in, and comply with the study procedures exclusion criteria: * has a history of allergy or anaphylactic reaction to neomycin, gelatin, or any component of varivax\^tm * has received any form of varicella or herpes zoster vaccine at any time prior to study, or anticipates receiving any during study * has received immune globulin, a blood transfusion or blood derived products within prior 5 months or plans to do so during study * has received aspirin or any aspirin-containing products within prior 14 days * has been exposed to varicella or herpes zoster in the prior 4 weeks involving playmate, hospital or continuous household contact, or had contact with a newborn whose mother had chickenpox 5 days before or 2 days after delivery * has, or lives with a person who has, any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity including those resulting from corticosteroid use or other immunosuppressive therapy * has received glucocorticosteroids for more than 5 consecutive days within prior 3 months, or any dose of glucocorticoids within prior 7 days, or expects to use glucocorticosteroids during the study * was vaccinated with licensed non-live or live vaccine within prior 30 days or expects vaccination during 42 day follow-up postvaccination period * had a fever within 72 hours prior to study vaccination * has participated in another trial within prior 30 days, is currently participating in another trial, or plans to participate in another trial during the planned study period for this trial * is pregnant or nursing
motor response to sildenafil in pd

Conditions: Parkinsons Disease; Erectile Dysfunction

Summary: sildenafil (viagra(r))is widely used by men with parkinsons disease (pd) and erectile dysfunction. a number of patients have reported that when they take sildenafil, their need of anti-pd medication is reduced. we hypotheses that sildenafil increases brain blood flow and hence improves the function of specific brain regions, improving motor function. motor function and cerebral blood flow of 8 patients will be tested before and after sildenafil intake and before and after anti-pd medication.

erectile dysfunction can be experienced by up tp 40% of men with parkinsons disease (pd). sildenafil (viagra(r))is widely used by men with pd and erectile dysfunction. a number of patients have reported that when they take sildenafil, their need of anti-pd medication is reduced. we hypotheses that sildenafil increases cerebral blood flow in basal ganglia and hence improves the function, improving motor function. motor function and cerebral blood flow (rcbf) of 8 patients will be tested before and after sildenafil intake and before and after anti-pd medication. rcbf will be measured by the xe133 inhalation method and a fast-rotating, brain-dedicated, single photon emission computerized tomograph (spect, tomomatic, 232, medimatic, inc., denmark). two scans will be perfomed, when patients are i)in normal medicated state and ii) in normal medicated state 1 hour after intake of 100 mg sildenafil. motor function will be measured i 4 conditions: i)in normal medicated state and ii) in normal medicated state 1 hour after intake of 100 mg sildenafil, iii) after 12 hours of discontiation of anti-pd mediciation and iiii) after 14 hours of discontiation of anti-pd mediciation and 1 hour after intake of 100 mg sildenafil.

Eligibility criteria:
inclusion criteria: * men * parkinsons disease * erectile dysfunction * previous tried sildenafil with beneficial effects on motor function exclusion criteria: * psychosis * heart disease
washing without water: cost-effectiveness of a rapidly spreading nursing intervention in bedridden patients'

Conditions: Skin Disease

Summary: the purpose of this study is to compare the traditional bed bath with 'washing without water' on * 1) effects on skin integrity * 2) patient and nurse satisfaction and 3) costs. in a cluster randomized trial we will randomize 50 nursing home wards (576 patients) to 'washing without water' or traditional bed baths. bathing regimens are continued for six weeks. whereas effects on skin damage are not likely to be specific for setting, these results can be generalized to other patient groups.

rapid implementation of new interventions while cost-effectiveness and acceptability for patients and care providers are unclear, is never desirable. 'washing without water' is such an intervention. the traditional bed bath is executed by using tap water, towels, washcloths and soap. as an alternative, 'washing without water' was recently introduced in the netherlands. this concept consists of disposable washcloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion. 'washing without water' can be used with all patients who need bathing assistance, especially when taking a shower or sitting in a hot tub is not possible. however, while several claims are made about the positive effects of 'washing without water' as compared to traditional bathing, evidence is lacking. also, 'washing without water' is controversial. while some are eager to adopt the new concept, others see it as 'efficiency gone loose' and denying patients one of the most basic elements of care: a proper bath. this study therefore addresses the cost effectiveness of 'washing without water' in bedridden patients.

Eligibility criteria:
inclusion criteria: * long stay psychogeriatric nursing home residents * long stay somatic nursing home residents * 100 randomly selected nurses from the participating nursing home wards exclusion criteria: -

Keywords: skin damage intertrigo dermatitis erythema aggression body wipes soaps no rinse cost effectiveness nursing home residents nurse
endophenotyping for plant-based food allergy diagnosis, tolerance biomarkers, and mechanisms in microneedle immunotherapy

Conditions: Food Allergies

Summary: in relation to the prognosis of vegetable fa (vfa), in contrast to other food allergies (fa), which disappear naturally with time, vfa tends to persist into adulthood and to the appearance of new sensitizations to other vegetables. the paradigm of early intervention in patients with risk factors for developing fa has changed in recent years, with evidence that maintaining a controlled diet with foods with potential allergic risk in a population of children at risk has shown efficacy in early intervention. an important aspect would be the selection of the dose of the food to be included in the diet. in this sense, recent studies on the standardization of the double-blind placebo-controlled oral challenge test (dbpcfc) in allergic patients to lipid transfer proteins (ltp) with known amounts of pru p 3 (peach ltp), have observed that the maximum tolerated dose (mtd) was equivalent to 40 grams of peach with skin. based on these results and those obtained in the pediatric population, this study aims to evaluate whether the maintenance in the diet of a dmt evaluated in a dbpcfc could influence tolerance (desensitization) to the food at both clinical and immunological levels.


Eligibility criteria:
inclusion criteria: * women and men * 14-65 years-old * peach allergy due to sensitization to ltp confirmed by skin tests and/or igee positive to pru p 3. * sign informed consent. exclusion criteria: * pregnant of lactating women. * patients with immunological diseases, mental illness or severe atopic dermatitis. * patients treated with immunomodulators and/or β-blockers * patients with forced expiratory volume (fev1)\<70%.

Keywords: vegetable food allergy allergy desensitization lipid transfer proteins
acute response capsaicin flare study

Conditions: Healthy

Summary: prior to administering pf-04427429 to patients we wish to increase the understanding of functional effects associated with calcitonin gene related peptide (cgrp) pathways. this study will examine whether it is possible for a single dose of pf-04427429 to acutely attenuate a capsaicin induced flare response.

proof of mechanism in healthy volunteers

Eligibility criteria:
inclusion criteria: * healthy male subjects between the ages of 18 and 50 years inclusive. healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests. * evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. * skintype i-iii with a distance from base of scaphoid to antecubital fossa \>26cm on their forearms. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, symptomatic, seasonal allergies at time of dosing). * use of biologics including any live vaccines within 3 months prior to screening or prior treatment with an antibody in a previous clinical trial or treatment with an immunoglobulin in the past 6 months. * 12-lead ecg demonstrating qtcf \>450 msec at screening. * subjects with scars or tattoos on the forearms, or with evidence of sunburn, or excessive hairy volar forearms.

Keywords: healthy male volunteers capsaicin challenge safety toleration